Top-Funded Digital Health Companies And Their Impact On High-Burden, High-Cost Conditions

Digital health companies hold promise to address major health care challenges, though little has been published on their impact. We identified the twenty top-funded private US-based digital health companies to analyze their products and services, related peer-reviewed evidence, and the potential for...

Full description

Saved in:
Bibliographic Details
Published inHealth Affairs Vol. 38; no. 1; pp. 115 - 123
Main Authors Safavi, Kyan, Mathews, Simon C., Bates, David W., Dorsey, E. Ray, Cohen, Adam B.
Format Journal Article
LanguageEnglish
Published United States The People to People Health Foundation, Inc., Project HOPE 01.01.2019
Subjects
Analytics
Artificial intelligence
Big Data
Biosensors
Clinical outcomes
Companies
Company publications
Consumers
Data management
Data processing
Digital technology
Disease
Effectiveness studies
Employees
False advertising
Funding
Genomics
Health care
Health care access
Health care expenditures
Health care industry
Health care policy
Impact factors
Intelligence
Internet
Medicaid
Medical equipment
Medicare
Patients
Personal health
Population studies
Risk factors
Technological change
Telemedicine
Volunteers
United States > US
Online AccessGet full text

Cover

More Information
Summary:Digital health companies hold promise to address major health care challenges, though little has been published on their impact. We identified the twenty top-funded private US-based digital health companies to analyze their products and services, related peer-reviewed evidence, and the potential for impact on patients with high-burden conditions. Data analytics (including artificial intelligence and big data) was the most common company type. Companies producing biosensors had the greatest funding. Publications were concentrated among a small number of companies. Healthy volunteers were most commonly studied. Few studies enrolled high-burden populations, and few measured their impact in terms of outcomes, cost, or access to care. These data suggest that leading digital health companies have not yet demonstrated substantial impact on disease burden or cost in the US health care system. Our findings indicate the importance of fostering an environment, with regard to policy and the consumer market, that encourages the development of evidence-based, high-impact products.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0278-2715
2694-233X
1544-5208
2694-233X
DOI:10.1377/hlthaff.2018.05081